08:00 , Feb 25, 2013 |  BC Week In Review  |  Financial News

Cytomedix proposes private placement of units

Cytomedix Inc. (OTCQX:CMXI), Gaithersburg, Md.   Business: Dermatology   Date announced: 2/20/13   Type: Private placement of units   To be raised: Up to $5 million   Units: 9.1 million   Price prior: $0.66   Placement agent: Burrill   Shares outstanding prior: 94.3...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

ALD-401: Interim Phase II data

Interim data from 10 patients in the double-blind, placebo-controlled, U.S. Phase II RECOVER-Stroke trial showed that an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke was safe with no severe adverse events reported....
07:00 , May 21, 2012 |  BC Week In Review  |  Clinical News

ALD-401: Phase II ongoing

Cytomedix said an independent DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase II RECOVER-Stroke trial based on a review of safety data from the first 10 patients. The trial is evaluating an intracarotid infusion...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Aldagen, Cytomedix deal

Wound and tissue repair company Cytomedix acquired regenerative cell therapy play Aldagen in a stock deal valued at about $16 million. Aldagen shareholders, who will own 17% of the combined company, are also eligible for...
02:14 , Feb 9, 2012 |  BC Extra  |  Company News

Cytomedix acquires Aldagen

Wound and tissue repair company Cytomedix Inc. (OTCBB:CMXI) acquired regenerative cell therapy play Aldagen Inc. (Durham, N.C.) in a stock deal valued at about $16 million. Aldagen shareholders, who will own 17% of the combined...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

ALD-401: Phase II started

Aldagen began a double-blind, sham-controlled, U.S. Phase II trial to evaluate an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke in about 100 patients. Aldagen Inc., Durham, N.C.   Product: ALD-401   Business: Neurology...
07:00 , May 16, 2011 |  BioCentury  |  Product Development

Stemming Stroke's Effects

Stroke has been a notoriously difficult condition to treat, but SanBio Co. Ltd. and ReNeuron Group plc think stem cell therapies can reverse the symptoms of disabled patients many months after the event. The companies...
07:00 , Apr 11, 2011 |  BioCentury  |  Finance

Second time no charm

Cell therapeutic company Aldagen Inc., which apparently is running very low on cash, last week withdrew its IPO for a second time. The company withdrew an IPO in 2008 and then refiled in 2009. In July...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Financial News

Aldagen withdraws IPO

Aldagen Inc., Durham, N.C.   Business: Gene/Cell therapy   Date announced: 4/5/11   Type: IPO   Underwriters: Boenning & Scattergood Inc.; Ladenburg Thalmann; National Securities   Note: Aldagen withdrew its IPO due to market conditions.   ...
00:43 , Apr 6, 2011 |  BC Extra  |  Financial News

Aldagen pulls IPO

Aldagen Inc. (Durham, N.C.) withdrew its IPO due to market conditions. In July 2010, the company amended its IPO to raise $40 million. Aldagen is preparing to begin a Phase II trial for ALD-401 to...